

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 August 2022 (18.08.2022)



(10) International Publication Number
WO 2022/173976 A1

(51) International Patent Classification:

C12N 15/11 (2006.01) A61K 48/00 (2006.01)

(21) International Application Number:

PCT/US2022/016015

(22) International Filing Date:

10 February 2022 (10.02.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/148,579 11 February 2021 (11.02.2021) US

(71) Applicant: **IONIS PHARMACEUTICALS, INC.**
[US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **MULLICK, Adam**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **BUI, Huynh-Hoa**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **FREIER, Susan M.**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **YEH, Ting Yuan**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US). **KUBLI, Dieter**; 2855 Gazelle Ct., Carlsbad, CA 92010 (US).

(74) Agent: **LIU, Jing** et al.; Sheppard Mullin Richter & Hampton LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, CA 92626 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOUNDS AND METHODS FOR REDUCING PLN EXPRESSION

(57) Abstract: Provided are oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLN RNA in a cell or animal, and in certain instances reducing the amount of PLN protein in a cell or animal. Such oligomeric agents, oligomeric compounds, methods, and pharmaceutical compositions are useful to treat cardiomyopathy, heart failure, or arrhythmia.

WO 2022/173976 A1